ArticleFuture science OA2026
Nomograms for the prognosis prediction model of early-stage triple-negative breast cancer - based on SEER database.
Article in Future science OA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nomograms for the prognosis prediction model of early-stage triple-negative breast cancer - based on SEER database.Future science OA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTriple-negative breast cancer (TNBC) is aggressive and unresponsive to hormone therapy, drawing widespread attention to its treatment and prognosis. This study aimed to summarize the prognosis of early-stage TNBC and construct nomograms to accurately predict survival and improve treatment strategies. PATIENTS &
methodsThe modeling group comprised early-stage TNBC patients from the SEER database. Prognostic factors were identified via Cox regression, and nomograms were developed using R software. A validating group with identical screening criteria was assembled from Sun Yat-sen University Cancer Center. Validation involved the Concordance index, Receiver Operating Characteristic curves, and calibration curves.
resultsThe modeling group included 14,389 patients and the validating group 1,146. Age and seven other factors were independent predictors (P < 0.05) and were incorporated into the nomograms. The C-indices for disease-free survival were 0.884 (95% CI: 0.876-0.892) in the modeling group and 0.686 (95% CI: 0.653-0.719) in the validating group. For overall survival, C-indices were 0.873 (95% CI: 0.863-0.883) and 0.741 (95% CI: 0.702-0.780), respectively.
conclusionsThe constructed nomograms demonstrated good predictive performance and may serve as practical tools for risk stratification in early-stage TNBC. However, given the observational nature of the data, the associations between treatment-related factors and survival should be interpreted with caution and warrant confirmation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.